Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031 ..., Market Research Report: MarketsandMarkets

Дата публикации: 06-08-2026 00:00:00

Основное содержимое страницы с новостью.

Healthcare

Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031

2026-2031

FORECAST PERIOD

MULTIOMICS MARKET SIZE, SHARE & GROWTH SNAPSHOT

multiomics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global multiomics market is projected to grow from USD 3.18 billion in 2026 to USD 5.70 billion by 2031, at a CAGR of 12.3% during the forecast period. The market was valued at USD 2.88 billion in 2025. The multiomics market encompasses the technologies, products, and services used to integrate and analyze multiple biological data layers, including genomics, transcriptomics, proteomics, epigenomics, and spatial omics. The market includes sequencing platforms, mass spectrometry systems, microarrays, single-cell and spatial analysis technologies, bioinformatics software, data analysis platforms, and associated consumables and services. It supports pharmaceutical and biotechnology companies, academic and research institutions, CROs/CDMOs, and healthcare organizations in applications such as drug discovery and development, biomarker identification, precision medicine, disease research, clinical research, and systems biology.

KEY TAKEAWAYS

MARKET SNAPSHOT:
Base Year Market Size (2025): USD 2.88 Billion
Current Market Size (2026): USD 3.18 Billion
Forecast Market Size (2031): USD 5.70 Billion
CAGR (2026–2031): 12.3%
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest market share of 44.2% in 2025.
Offering Leader: Products segment accounted for the largest market share of 43.4% in 2025.
Method Leader: Spatial omics is the fastest-growing segment, projected to register a CAGR of 13.8% during the forecast period.
Technology Leader: Sequencing accounted for the largest share of 37.5% in 2025 and is projected to register the highest CAGR of 13.2% during the forecast period.
End User Leader: Pharmaceutical & biotechnology companies dominated the market, accounting for 44% of the market in 2025.
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
10x Genomics, Thermo Fisher Scientific Inc., Illumina, Inc., and Oxford Nanopore Technologies plc were identified as some of the star players in the global multiomics market, given their strong market share and product and service footprint.
RayBiotech, Inc. (US) and Azenta, Inc. have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The global multiomics market is expanding steadily, driven by the growing demand for integrated biological data analysis, increasing investments in precision medicine and biopharmaceutical research, and rising adoption of advanced multiomics technologies across drug discovery, biomarker research, clinical research, and translational applications.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The global multiomics market is expanding steadily, driven by growing demand for integrated biological data analysis, increasing investments in precision medicine and biopharmaceutical research, and rising adoption of genomics, transcriptomics, proteomics, epigenomics, and spatial omics technologies across drug discovery, biomarker identification, disease research, clinical research, and translational applications.

multiomics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

OPPORTUNITIES

Impact
Level

Lack of standardization across multiomics workflows

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Increasing adoption of multiomics in precision medicine and disease research is driving demand for integrated molecular profiling technologies that enable comprehensive disease characterization, biomarker discovery, patient stratification, and targeted treatment development.

High computational requirements, complex data integration processes, diverse analytical platforms, and the need for specialized bioinformatics expertise continue to increase operational complexity and constrain the broader adoption of multiomics technologies.

Emerging applications of spatial proteomics are creating new opportunities for high-resolution tissue analysis, biomarker discovery, disease characterization, and precision medicine by enabling molecular profiling while preserving spatial information.

Scaling multiomics workflows across research and clinical applications remains challenging because of variations in sample preparation, assay technologies, data formats, analytical methods, and quality-control procedures, which can affect reproducibility and data comparability.

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology.	Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
	Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms.	Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The global multiomics market is a highly interconnected ecosystem in which pharmaceutical and biotechnology companies, academic institutions, research organizations, and healthcare providers collaborate to generate, integrate, and interpret data across genomics, transcriptomics, proteomics, metabolomics, epigenomics, and spatial omics. Technology providers offer advanced sequencing, mass spectrometry, single-cell, spatial analysis, and bioinformatics platforms, along with associated reagents, consumables, and data analysis solutions. Contract research organizations (CROs) and specialized service providers support sample processing, multiomic profiling, data integration, bioinformatics, and biomarker discovery across research and clinical development stages. Regulatory authorities and healthcare systems across regions such as North America and Europe establish evolving standards for data quality, clinical validation, privacy, and analytical reproducibility, driving innovation, interoperability, compliance, and the adoption of multiomics in precision medicine, drug discovery, disease research, and translational applications.

multiomics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

multiomics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

In 2025, products accounted for the largest share, supported by the widespread adoption of sequencing platforms, mass spectrometry systems, reagents, kits, and other consumables required for multiomic analysis.

Single-cell omics accounted for the largest share of the global multiomics market in 2025, driven by its ability to characterize genomic, transcriptomic, epigenomic, and proteomic profiles at cellular resolution.

Sequencing & analysis/sample characterization accounted for the largest share of the global multiomics market in 2025, supported by the growing use of sequencing and analytical workflows for generating comprehensive molecular profiles.

Sequencing technologies accounted for the largest share of the global multiomics market in 2025, driven by advances in high-throughput, single-cell, long-read, and spatial sequencing technologies and their expanding applications in disease research, precision medicine, and drug discovery.

Oncology accounted for the largest share of the global multiomics market in 2025, supported by the increasing use of integrated molecular profiling to understand tumor heterogeneity, identify biomarkers, and guide precision treatment.

Pharmaceutical & biotechnology companies accounted for the largest share of the global multiomics market in 2025, driven by the increasing adoption of multiomic technologies for drug discovery, biomarker identification, precision medicine, and translational research.

REGION Asia Pacific to be fastest-growing region in market during forecast period

During the forecast period, Asia Pacific is expected to witness rapid growth in the multiomics market, driven by increasing investments in genomics and precision medicine, expanding biotechnology and pharmaceutical research, and the growing adoption of advanced sequencing, single-cell, spatial omics, and bioinformatics technologies. The expansion of CRO services, research infrastructure, and healthcare applications further supports regional market growth.

multiomics-market Region

MULTIOMICS MARKET: COMPANY EVALUATION MATRIX

In the global multiomics market, 10x Genomics is the star player, driven by its strong portfolio of single-cell and spatial omics technologies, including solutions that enable integrated analysis of genomic, transcriptomic, epigenomic, and spatial data. The company maintains its leadership through continuous technological innovation, strong adoption across research and biopharmaceutical organizations, and strategic collaborations with academic and healthcare institutions. Biognosys is an emerging leader, supported by its advanced mass spectrometry-based proteomics and multiomics capabilities. The company's growing focus on high-throughput proteomic analysis, biomarker discovery, and data-driven biological insights positions it strongly to benefit from the rising demand for integrated multiomics research and precision medicine applications.

multiomics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2025 (Value)	USD 2.88 Billion
Market Size in 2026 (Value)	USD 3.18 Billion
Market Forecast in 2031 (Value)	USD 5.70 Billion
Growth Rate	12.3%
Years Considered	2024–2031
Base Year	2025
Forecast Period	2026–2031
Units Considered	Value (USD Million/Billion)
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Offering: Products (Consumables Instruments/Systems & Software) Services By Method: Single-cell Omics (Single-cell Transcriptomics Single-cell Epigenomics Single-cell Proteomics Single-cell Genomics and Other Single-cell Omics) Proteomics (NGS-based Proteomics PCR-based Proteomics Mass Spectrometry (MS)-based Proteomics and Other Proteomics Methods) Spatial Omics (Spatial Transcriptomics Spatial Proteomics Spatial Epigenomics Spatial Genomics and Other Spatial Omics) Long-read & Long-range Sequencing (Long-read Sequencing Long-range Sequencing Other Methods) Epigenomics (Sequencing-based Epigenomics [DNA Methylation Sequencing Chromatin Accessibility Sequencing Histone Modification Profiling and Chromatin Interaction Analysis] Other Epigenomics Methods) and Other Methods By Technology: Sequencing (Long-read Sequencing [Nanopore Sequencing and Single-molecule Real-time (SMRT) Sequencing] Other Sequencing Technologies) Proteomics Technologies Other Technologies By Workflow: Sample Preparation Sequencing & Analysis/Sample Characterization Data Visualization & Analysis By Application: Oncology Cell Biology Immunology Neurology Precision Medicine Biomarker Discovery Translational Research Drug Discovery & Development Clinical Diagnostics Other Applications By End User: Pharmaceutical & Biotechnology Companies Academic & Research Institutes Hospital & Diagnostic/Clinical Laboratories CROs & CDMOs
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: MULTIOMICS MARKET REPORT CONTENT GUIDE

multiomics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Evaluate the competitive positioning of key players in the multiomics market	Benchmarked leading companies across sequencing, single-cell, spatial omics, proteomics, metabolomics, bioinformatics, and integrated multiomics platforms based on technology capabilities, workflow coverage, product and service offerings, geographic reach, and end-user focus	Identifies competitive gaps, technology differentiation opportunities, strategic partnerships, and market positioning strategies
Assess high-growth multiomics technologies and application opportunities	Evaluated growth potential across genomics, transcriptomics, proteomics, metabolomics, epigenomics, single-cell multiomics, spatial omics, and AI-enabled data integration technologies	Supports investment prioritization, technology development, product portfolio expansion, and service diversification strategies

RECENT DEVELOPMENTS

June 2026 : 10x Genomics acquired Proteintech Genomics to expand high-plex proteomics across its single-cell and spatial portfolios. The acquired Human Discovery Panel enables simultaneous measurement of intracellular and cell-surface proteins alongside transcriptomic information.
June 2026 : Thermo Fisher launched an integrated set of mass spectrometry and software solutions for multiomics, advanced proteomics, structural biology, biopharmaceutical characterization, and small-molecule analysis. The Orbitrap Tribrid Apex platform combines three mass analyzers with AI-enabled proteomics and proteoform-analysis software.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

MARKET OVERVIEW

Precision medicine surges with multiomics, despite integration complexity and high costs.

4.2.1.1

RISING USE OF MULTIOMICS IN PRECISION MEDICINE AND DISEASE STRATIFICATION

4.2.1.2

RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS

4.2.1.3

INCREASING ACCESSIBILITY OF HIGH-QUALITY, INTEGRATED OMICS DATA FOR RESEARCH

4.2.1.4

AI, MACHINE LEARNING, AND CLOUD BIOINFORMATICS IMPROVING CROSS-OMICS INTERPRETATION

4.2.2.1

COMPLEXITY OF MULTIOMICS DATA INTEGRATION AND STANDARDIZATION

4.2.2.2

HIGH COSTS CONSTRAIN TECHNOLOGY ADOPTION

4.2.3.1

GROWING ADOPTION OF SPATIAL PROTEOMICS FOR TISSUE-CONTEXT ANALYSIS AND BIOMARKER DISCOVERY

4.2.3.2

INCREASING EMERGENCE OF SINGLE-CELL PROTEOMICS FOR HIGH-RESOLUTION CHARACTERIZATION OF CELLULAR PROFILES

4.2.4.1

LACK OF STANDARDIZATION ACROSS MULTIOMICS WORKFLOWS

4.3

UNMET NEEDS AND WHITE SPACES

4.4

INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.5

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

INDUSTRY TRENDS

Navigate evolving industry dynamics with strategic insights from comprehensive multiomics and pricing trend analyses.

5.1

PORTER’S FIVE FORCES ANALYSIS

5.1.1

THREAT OF NEW ENTRANTS

5.1.2

THREAT OF SUBSTITUTES

5.1.3

BARGAINING POWER OF BUYERS

5.1.4

BARGAINING POWER OF SUPPLIERS

5.1.5

INTENSITY OF COMPETITIVE RIVALRY

5.2

MACROECONOMIC OUTLOOK

5.2.2

GDP TRENDS AND FORECAST

5.2.3

TRENDS IN GLOBAL HEALTHCARE INDUSTRY

5.2.4

TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY

5.5.1

AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025)

5.5.2

AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025

5.5.3

AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025

5.6.1

IMPORT DATA FOR HS CODE 9027

5.6.2

EXPORT DATA FOR HS CODE 9027

5.6.3

IMPORT VOLUME FOR HS CODE 9027

5.6.4

EXPORT VOLUME FOR HS CODE 9027

5.7

KEY CONFERENCES & EVENTS

5.8

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.9

INVESTMENT/FUNDING ACTIVITY

5.10.1

ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION

5.10.2

INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH

5.10.3

MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY

5.11

IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET

5.11.3

PRICE IMPACT ANALYSIS

5.11.4

IMPACT ON COUNTRIES/REGIONS

5.11.5

IMPACT ON END-USE INDUSTRIES

5.11.5.1

PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

5.11.5.2

HOSPITALS AND DIAGNOSTIC LABORATORIES

5.11.5.3

ACADEMIC & RESEARCH INSTITUTES

TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

AI-driven multiomics innovations propel future-ready applications and reshape market dynamics.

6.1.1

SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING

6.1.2

SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING

6.1.3

HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS

6.2

ADJACENT TECHNOLOGIES

6.2.1

MICROARRAYS AND HYBRIDIZATION-BASED PROFILING

6.2.2

DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING

6.3

COMPLEMENTARY TECHNOLOGIES

6.3.1

MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING

6.3.2

HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY

6.4

TECHNOLOGY/PRODUCT ROADMAP

6.5.1

TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025

6.7

IMPACT OF AI/GEN AI ON MULTIOMICS MARKET

6.7.1

TOP USE CASES AND MARKET POTENTIAL

6.7.2

BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS

6.7.3

CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET

6.7.4

INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS

6.7.5

CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET

REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

Navigate global regulatory complexities to drive impactful sustainability initiatives and eco-certifications.

107

7.1

REGIONAL REGULATIONS AND COMPLIANCE

7.1.1

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.2

SUSTAINABILITY INITIATIVES

7.3

IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES

7.4

CERTIFICATIONS, LABELING, AND ECO-STANDARDS

MULTIOMICS MARKET, BY OFFERING

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 45 Data Tables

113

8.2.1.1

INCREASING EXPERIMENT VOLUMES, HIGHER MULTIPLEXING, AND RECURRING REAGENT REQUIREMENTS SUPPORT GROWTH

8.2.1.2

ASSAY KITS & REAGENTS

8.2.1.2.1

RECURRING ASSAY CONSUMPTION, HIGHER MULTIPLEXING, AND IMPROVED LOW-INPUT PERFORMANCE DRIVE MARKET GROWTH

8.2.1.3

OTHER CONSUMABLES

8.2.2

INSTRUMENTS & SOFTWARE

8.2.2.1

INTEGRATED MULTIOMICS PLATFORMS, AUTOMATED WORKFLOWS, AND AI-ENABLED DATA INTERPRETATION STRENGTHEN DEMAND

8.3.1

RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH

MULTIOMICS MARKET, BY TECHNOLOGY

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 52 Data Tables

132

9.2.1

LONG-READ SEQUENCING

9.2.1.1

NANOPORE SEQUENCING

9.2.1.1.1

REAL-TIME NATIVE-MOLECULE ANALYSIS, SCALABLE PLATFORMS, AND INTEGRATED GENOMIC–EPIGENOMIC READOUTS ARE ACCELERATING NANOPORE SEQUENCING ADOPTION

9.2.1.2.1

HIGH-ACCURACY HIFI READS AND LOWER SEQUENCING COST TO EXPAND SMRT-BASED MULTIOMICS

9.2.2

OTHER SEQUENCING TECHNOLOGIES

9.3.1

ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH

MULTIOMICS MARKET, BY METHOD

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 210 Data Tables

154

10.2.1

IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH

10.2.2

SINGLE-CELL TRANSCRIPTOMICS

10.2.2.1

HIGHER SAMPLE THROUGHPUT, IMPROVED CELL RECOVERY, AND COMPATIBILITY WITH FIXED CLINICAL SAMPLES ARE EXPANDING SINGLE-CELL TRANSCRIPTOMICS

10.2.3

SINGLE-CELL EPIGENOMICS

10.2.3.1

GROWING INTEREST IN GENE REGULATION, CHROMATIN STATE, AND TREATMENT RESISTANCE IS ACCELERATING SINGLE-CELL EPIGENOMICS RESEARCH

10.2.4

SINGLE-CELL PROTEOMICS

10.2.4.1

ULTRASENSITIVE MASS SPECTROMETRY AND HIGHER-THROUGHPUT PROTEIN QUANTIFICATION EXPANDING FUNCTIONAL ANALYSIS AT SINGLE-CELL RESOLUTION

10.2.5

SINGLE-CELL GENOMICS

10.2.5.1

IMPROVED DETECTION OF CLONAL VARIATION AND SIMULTANEOUS GENOTYPE-PHENOTYPE ANALYSIS ARE DRIVING SINGLE-CELL GENOMICS ADOPTION

10.2.6

OTHER SINGLE-CELL OMICS

10.3.1

MS-BASED PROTEOMICS

10.3.1.1

DATA-INDEPENDENT ACQUISITION AND IMPROVED QUANTITATIVE DEPTH TO SUSTAIN MS-BASED PROTEOMICS LEADERSHIP

10.3.2

NGS-BASED PROTEOMICS

10.3.2.1

SEQUENCING READOUTS AND ULTRA-HIGH-PLEX PANELS TO MAKE NGS-BASED PROTEOMICS THE FASTEST-GROWING PROTEOMICS METHOD

10.3.3

PCR-BASED PROTEOMICS

10.3.3.1

SENSITIVE PROXIMITY-AMPLIFICATION ASSAYS TO SUPPORT TARGETED, LOW-VOLUME PROTEIN PROFILING

10.3.4

OTHER PROTEOMICS METHODS

10.4.1

SPATIAL TRANSCRIPTOMICS

10.4.1.1

WHOLE-TRANSCRIPTOME TISSUE MAPPING AND HIGHER RESOLUTION TO SUSTAIN SPATIAL TRANSCRIPTOMICS LEADERSHIP

10.4.2

SPATIAL PROTEOMICS

10.4.2.1

HIGHER-PLEX IMAGING AND TISSUE PHENOTYPING TO ACCELERATE SPATIAL PROTEOMICS ADOPTION

10.4.3

SPATIAL EPIGENOMICS

10.4.3.1

MAPPING REGULATORY STATES WITHIN TISSUE TO EXPAND SPATIAL EPIGENOMICS FROM EARLY RESEARCH APPLICATIONS

10.4.4.1

IN SITU VARIANT AND COPY-NUMBER MAPPING TO SUPPORT SPATIAL GENOMICS GROWTH

10.4.5

OTHER SPATIAL OMICS

10.5

LONG-READ & LONG-RANGE SEQUENCING

10.5.1

IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION

10.5.2

LONG-READ SEQUENCING

10.5.2.1

HIGHER ACCURACY AND THROUGHPUT TO ENSURE MARKET LEADERSHIP

10.5.3

LONG-RANGE SEQUENCING

10.5.3.1

GENOME MAPPING AND LINKED INFORMATION TO IMPROVE STRUCTURAL AND HAPLOTYPE CHARACTERIZATION

10.5.4

OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS

10.6.1

SEQUENCING-BASED EPIGENOMICS

10.6.1.1

DNA METHYLATION SEQUENCING

10.6.1.1.1

GENOME-WIDE AND TARGETED METHYLATION ANALYSIS TO SUSTAIN THE LARGEST SEQUENCING-BASED EPIGENOMICS SHARE

10.6.1.2

CHROMATIN ACCESSIBILITY SEQUENCING

10.6.1.2.1

ATAC-SEQ ADOPTION AND REGULATORY ELEMENT MAPPING TO MAKE ACCESSIBILITY PROFILING THE FASTEST-GROWING EPIGENOMICS METHOD

10.6.1.3

HISTONE MODIFICATION PROFILING

10.6.1.3.1

LOWER-INPUT CHROMATIN PROFILING TO BROADEN ANALYSIS OF HISTONE-ASSOCIATED REGULATORY STATES

10.6.1.4

CHROMATIN INTERACTION ANALYSIS

10.6.1.4.1

3D GENOME MAPPING TO CONNECT DISTAL REGULATORY ELEMENTS WITH GENE ACTIVITY

10.6.2

OTHER EPIGENOMICS METHODS

MULTIOMICS MARKET, BY WORKFLOW

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables

237

11.2

SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION

11.2.1

HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS

11.3.1

IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES

11.4

DATA VISUALIZATION & ANALYSIS

11.4.1

AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS

MULTIOMICS MARKET, BY APPLICATION

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 71 Data Tables

248

12.2.1

GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP

12.3

DRUG DISCOVERY & DEVELOPMENT

12.3.1

DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION

12.4.1

LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH

12.5.1

INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT

12.6.1

CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE

12.7.1

HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY

12.8

TRANSLATIONAL RESEARCH

12.8.1

IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH

12.9.1

BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS

12.10

CLINICAL DIAGNOSTICS

12.10.1

GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION

MULTIOMICS MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables

277

13.2

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

13.2.1

EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION

13.3

ACADEMIC & RESEARCH INSTITUTES

13.3.1

GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES

13.4.1

OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS

13.5

HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES

13.5.1

CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES

MULTIOMICS MARKET, BY REGION

Comprehensive coverage of 7 Regions with country-level deep-dive of 15 Countries | 439 Data Tables.

290

14.2.1.1

REGULATORY ACCEPTANCE, CLINICALLY INTEGRATED MOLECULAR TESTING, AND POPULATION-SCALE HEALTH DATASETS ACCELERATE MULTIOMICS ADOPTION

14.2.2.1

POPULATION-SCALE PRECISION HEALTH INITIATIVES EXPAND INTEGRATION CAPACITY

14.3.1.1

CLINICAL INTEGRATION OF GENOME SEQUENCING AND STRONG TRANSLATIONAL RESEARCH NETWORKS DRIVE MARKET GROWTH

14.3.2.1

POPULATION-SCALE MULTIMODAL DATASETS, NHS INTEGRATION, AND INDUSTRY-BACKED BIOMARKER PROGRAMS PROPEL MARKET GROWTH

14.3.3.1

STANDARDIZED PRECISION-MEDICINE PATHWAYS AND STRONG ONCOLOGY RESEARCH NETWORKS DRIVE MARKET

14.3.4.1

SHARED RESEARCH INFRASTRUCTURE WIDENING ACCESS BEYOND LEADING ACADEMIC CENTERS

14.3.5.1

HOSPITAL-LINKED GENOMICS PROGRAMS SUPPORT STEADY ADOPTION OF INTEGRATED PROFILING

14.4.1.1

LARGE-SCALE GENOMIC INITIATIVES AND RAPID ADOPTION OF PRECISION MEDICINE TECHNOLOGIES DRIVE GROWTH

14.4.2.1

MATURE BIOBANKS AND PHARMACEUTICAL RESEARCH SUPPORT STABLE, HIGH-VALUE ADOPTION

14.4.3.1

NATIONAL BIO-DATA INFRASTRUCTURE AND DIGITAL-HEALTH CAPABILITIES ACCELERATE MULTIOMICS USE

14.4.4.1

GENOMEINDIA AND EXPANDING TRANSLATIONAL CAPACITY PROPEL RAPID GROWTH IN INDIAN MULTIOMICS MARKET

14.4.5.1

MISSION-LED GENOMICS INVESTMENT STRENGTHENS CLINICAL TRANSLATION AND DATA INTEGRATION

14.4.6

REST OF ASIA PACIFIC

14.5.1.1

GROWING GENOMICS INFRASTRUCTURE AND INCREASING PRECISION MEDICINE ADOPTION DRIVE MARKET GROWTH

14.5.2

REST OF LATIN AMERICA

14.6.1.1.1

RISING HEALTHCARE EXPENDITURE, EXPANDING GENOMICS RESEARCH, AND INVESTMENTS IN PRECISION MEDICINE TO PROPEL MARKET

14.6.1.2.1

LARGE-SCALE CITIZEN SEQUENCING MOVES GENOMICS TOWARD PREVENTIVE AND PERSONALIZED CARE

14.6.1.3

REST OF GCC COUNTRIES

14.6.2

REST OF MIDDLE EAST

14.7.1

DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE

COMPETITIVE LANDSCAPE

Discover strategic maneuvers shaping market dominance and emerging leaders in the multiomics landscape.

451

15.2

KEY PLAYER STRATEGIES/RIGHT TO WIN

15.2.1

OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET

15.3

REVENUE ANALYSIS, 2021–2025

15.4

MARKET SHARE ANALYSIS, 2025

15.5

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025

15.5.5

COMPANY FOOTPRINT: KEY PLAYERS, 2025

15.5.5.1

COMPANY FOOTPRINT

15.5.5.2

REGION FOOTPRINT

15.5.5.3

OFFERING FOOTPRINT

15.5.5.4

TECHNOLOGY FOOTPRINT

15.5.5.5

WORKFLOW FOOTPRINT

15.6

COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025

15.6.1

PROGRESSIVE COMPANIES

15.6.2

RESPONSIVE COMPANIES

15.6.5

COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025

15.6.5.1

DETAILED LIST OF KEY STARTUPS/SMES

15.6.5.2

COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

15.7

COMPANY VALUATION AND FINANCIAL METRICS

15.8

BRAND/PRODUCT COMPARISON

15.9

COMPETITIVE SCENARIO

15.9.1

PRODUCT & SERVICE LAUNCHES

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

470

16.1.1.1

BUSINESS OVERVIEW

16.1.1.2

PRODUCTS & SERVICES OFFERED

16.1.1.3

RECENT DEVELOPMENTS

16.1.1.3.1

PRODUCT & SERVICE LAUNCHES

16.1.1.4.2

STRATEGIC CHOICES

16.1.1.4.3

WEAKNESSES AND COMPETITIVE THREATS

16.1.2

THERMO FISHER SCIENTIFIC INC.

16.1.4

OXFORD NANOPORE TECHNOLOGIES PLC

16.1.7

DANAHER CORPORATION

16.1.9

AGILENT TECHNOLOGIES, INC.

16.1.14

WATERS CORPORATION

16.1.15

BIO-RAD LABORATORIES, INC.

16.2.1

BGI GENOMICS CO., LTD.

16.2.2

NOVOGENE CO., LTD.

16.2.5

MEDGENOME LABS LTD.

16.2.8

SAPIENT BIOANALYTICS, LLC

16.2.10

SOURCE BIOSCIENCE LTD.

RESEARCH METHODOLOGY

556

17.2

MARKET ESTIMATION METHODOLOGY

17.2.1

MARKET SIZE ESTIMATION

17.2.2

INSIGHTS OF PRIMARY EXPERTS

17.3

MARKET GROWTH RATE PROJECTIONS

17.4

MARKET BREAKDOWN AND DATA TRIANGULATION

17.5

RESEARCH ASSUMPTIONS

17.6

RESEARCH LIMITATIONS

18.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

18.3

CUSTOMIZATION OPTIONS

TABLE 1

MULTIOMICS MARKET: IMPACT ANALYSIS

TABLE 2

MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS

TABLE 3

MULTIOMICS MARKET: ROLE IN ECOSYSTEM

TABLE 4

AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)

TABLE 5

AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD)

TABLE 6

AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2023–2025 (USD)

TABLE 7

AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2023–2025 (USD)

TABLE 8

IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND)

TABLE 9

EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND)

TABLE 10

IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS)

TABLE 11

EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS)

TABLE 12

MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027

TABLE 13

US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 14

INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026

TABLE 15

CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET

TABLE 16

CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET

TABLE 17

NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18

EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 19

ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 20

REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 21

MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 22

MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 23

MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 24

NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 25

EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 26

ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 27

LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 28

MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 29

GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 30

MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 31

MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 32

NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 33

EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 34

ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 35

LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 36

MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 37

GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 38

ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 39

NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 40

EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 41

ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 42

LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 43

MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 44

GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 45

OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 46

NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 47

EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 48

ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 49

LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 50

MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 51

GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 52

MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 53

NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 54

EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 55

ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 56

LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 57

MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 58

GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 59

MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 60

NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 61

EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 62

ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 63

LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 64

MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 65

GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 66

MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 67

SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 68

SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 69

NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 70

EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 71

ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 72

LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 73

MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 74

GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 75

LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 76

LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 77

NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 78

EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 79

ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 80

LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 81

MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 82

GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 83

NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 84

NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 85

EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 86

ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 87

LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 88

MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 89

GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 90

SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 91

NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 92

EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 93

ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 94

LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 95

MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 96

GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 97

OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 98

NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 99

EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 100

ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 101

LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 102

MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 103

GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 104

PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 105

NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 106

EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 107

ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 108

LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 109

MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 110

GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 111

OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 112

NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 113

EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 114

ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 115

LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 116

MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 117

GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 118

MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 119

SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 120

SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 121

NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 122

EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 123

ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 124

LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 125

MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 126

GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 127

SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 128

NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 129

EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 130

ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 131

LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 132

MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 133

GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 134

SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 135

NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 136

EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 137

ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 138

LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 139

MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 140

GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 141

SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 142

NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 143

EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 144

ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 145

LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 146

MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 147

GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 148

SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 149

NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 150

EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 151

ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 152

LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 153

MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 154

GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 155

OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 156

NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 157

EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 158

ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 159

LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 160

MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 161

GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 162

PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 163

PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 164

NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 165

EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 166

ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 167

LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 168

MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 169

GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 170

MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 171

NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 172

EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 173

ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 174

LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 175

MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 176

GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 177

NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 178

NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 179

EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 180

ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 181

LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 182

MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 183

GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 184

PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 185

NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 186

EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 187

ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 188

LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 189

MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 190

GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 191

OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 192

NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 193

EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 194

ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 195

LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 196

MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 197

GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 198

SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 199

SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 200

NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 201

EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 202

ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 203

LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 204

MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 205

GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 206

SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 207

NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 208

EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 209

ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 210

LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 211

MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 212

GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 213

SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 214

NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 215

EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 216

ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 217

LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 218

MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 219

GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 220

SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 221

NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 222

EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 223

ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 224

LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 225

MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 226

GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 227

SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 228

NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 229

EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 230

ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 231

LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 232

MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 233

GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 234

OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 235

NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 236

EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 237

ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 238

LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 239

MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 240

GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 241

LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 242

LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 243

NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 244

EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 245

ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 246

LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 247

MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 248

GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 249

LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 250

NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 251

EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 252

ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 253

LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 254

MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 255

GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 256

LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 257

NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 258

EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 259

ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 260

LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 261

MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 262

GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 263

OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 264

NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 265

EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 266

ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 267

LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 268

MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 269

GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 270

EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 271

EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 272

NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 273

EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 274

ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 275

LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 276

MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 277

GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 278

SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 279

SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 280

NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 281

EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 282

ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 283

LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 284

MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 285

GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 286

DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 287

NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 288

EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 289

ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 290

LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 291

MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 292

GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 293

CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 294

NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 295

EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 296

ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 297

LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 298

MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 299

GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 300

HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 301

NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 302

EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 303

ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 304

LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 305

MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 306

GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 307

CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 308

NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 309

EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 310

ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 311

LATIN AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 312

MIDDLE EAST: CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 313

GCC COUNTRIES: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 314

OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 315

NORTH AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 316

EUROPE: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 317

ASIA PACIFIC: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 318

LATIN AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 319

MIDDLE EAST: OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 320

GCC COUNTRIES: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 321

OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 322

NORTH AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 323

EUROPE: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 324

ASIA PACIFIC: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 325

LATIN AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 326

MIDDLE EAST: OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 327

GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 328

MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 329

SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 330

NORTH AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 331

EUROPE: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 332

ASIA PACIFIC: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 333

LATIN AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 334

MIDDLE EAST: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 335

GCC COUNTRIES: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 336

SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 337

NORTH AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 338

EUROPE: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 339

ASIA PACIFIC: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 340

LATIN AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 341

MIDDLE EAST: SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 342

GCC COUNTRIES: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 343

DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 344

NORTH AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 345

EUROPE: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 346

ASIA PACIFIC: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 347

LATIN AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 348

MIDDLE EAST: DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 349

GCC COUNTRIES: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 350

MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 351

ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 352

NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 353

EUROPE: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 354

ASIA PACIFIC: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 355

LATIN AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 356

MIDDLE EAST: ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 357

GCC COUNTRIES: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 358

DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 359

NORTH AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 360

EUROPE: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 361

ASIA PACIFIC: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 362

LATIN AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 363

MIDDLE EAST: DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 364

GCC COUNTRIES: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 365

IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 366

NORTH AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 367

EUROPE: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 368

ASIA PACIFIC: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 369

LATIN AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 370

MIDDLE EAST: IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 371

GCC COUNTRIES: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 372

PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 373

NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 374

EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 375

ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 376

LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 377

MIDDLE EAST: PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 378

GCC COUNTRIES: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 379

BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 380

NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 381

EUROPE: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 382

ASIA PACIFIC: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 383

LATIN AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 384

MIDDLE EAST: BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 385

GCC COUNTRIES: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 386

CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 387

NORTH AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 388

EUROPE: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 389

ASIA PACIFIC: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 390

LATIN AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 391

MIDDLE EAST: CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 392

GCC COUNTRIES: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 393

TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 394

NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 395

EUROPE: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 396

ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 397

LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 398

MIDDLE EAST: TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 399

GCC COUNTRIES: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 400

NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 401

NORTH AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 402

EUROPE: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 403

ASIA PACIFIC: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 404

LATIN AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 405

MIDDLE EAST: NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 406

GCC COUNTRIES: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 407

CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 408

NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 409

EUROPE: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 410

ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 411

LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 412

MIDDLE EAST: CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 413

GCC COUNTRIES: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 414

OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 415

NORTH AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 416

EUROPE: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 417

ASIA PACIFIC: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 418

LATIN AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 419

MIDDLE EAST: OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 420

GCC COUNTRIES: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 421

MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 422

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 423

NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 424

EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 425

ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 426

LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 427

MIDDLE EAST: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 428

GCC COUNTRIES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 429

ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 430

NORTH AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 431

EUROPE: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 432

ASIA PACIFIC: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 433

LATIN AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 434

MIDDLE EAST: ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 435

GCC COUNTRIES: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 436

CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 437

NORTH AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 438

EUROPE: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 439

ASIA PACIFIC: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 440

LATIN AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 441

MIDDLE EAST: CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 442

GCC COUNTRIES: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 443

HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 444

NORTH AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 445

EUROPE: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 446

ASIA PACIFIC: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 447

LATIN AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 448

MIDDLE EAST: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 449

GCC COUNTRIES: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 450

MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 451

NORTH AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 452

NORTH AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 453

NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 454

NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 455

NORTH AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 456

NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 457

NORTH AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 458

NORTH AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 459

NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 460

NORTH AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 461

NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 462

NORTH AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 463

NORTH AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 464

NORTH AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 465

NORTH AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 466

NORTH AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 467

NORTH AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 468

US: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 469

US: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 470

US: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 471

US: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 472

US: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 473

US: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 474

US: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 475

US: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 476

US: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 477

US: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 478

US: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 479

US: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 480

US: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 481

US: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 482

US: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 483

US: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 484

CANADA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 485

CANADA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 486

CANADA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 487

CANADA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 488

CANADA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 489

CANADA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 490

CANADA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 491

CANADA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 492

CANADA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 493

CANADA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 494

CANADA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 495

CANADA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 496

CANADA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 497

CANADA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 498

CANADA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 499

CANADA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 500

EUROPE: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 501

EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 502

EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 503

EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 504

EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 505

EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 506

EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 507

EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 508

EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 509

EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 510

EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 511

EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 512

EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 513

EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 514

EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 515

EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 516

EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 517

GERMANY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 518

GERMANY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 519

GERMANY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 520

GERMANY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 521

GERMANY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 522

GERMANY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 523

GERMANY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 524

GERMANY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 525

GERMANY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 526

GERMANY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 527

GERMANY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 528

GERMANY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 529

GERMANY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 530

GERMANY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 531

GERMANY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 532

GERMANY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 533

UK: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 534

UK: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 535

UK: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 536

UK: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 537

UK: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 538

UK: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 539

UK: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 540

UK: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 541

UK: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 542

UK: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 543

UK: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 544

UK: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 545

UK: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 546

UK: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 547

UK: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 548

UK: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 549

FRANCE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 550

FRANCE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 551

FRANCE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 552

FRANCE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 553

FRANCE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 554

FRANCE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 555

FRANCE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 556

FRANCE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 557

FRANCE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 558

FRANCE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 559

FRANCE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 560

FRANCE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 561

FRANCE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 562

FRANCE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 563

FRANCE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 564

FRANCE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 565

ITALY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 566

ITALY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 567

ITALY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 568

ITALY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 569

ITALY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 570

ITALY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 571

ITALY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 572

ITALY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 573

ITALY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 574

ITALY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 575

ITALY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 576

ITALY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 577

ITALY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 578

ITALY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 579

ITALY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 580

ITALY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 581

SPAIN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 582

SPAIN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 583

SPAIN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 584

SPAIN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 585

SPAIN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 586

SPAIN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 587

SPAIN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 588

SPAIN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 589

SPAIN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 590

SPAIN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 591

SPAIN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 592

SPAIN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 593

SPAIN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 594

SPAIN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 595

SPAIN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 596

SPAIN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 597

REST OF EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 598

REST OF EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 599

REST OF EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 600

REST OF EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 601

REST OF EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 602

REST OF EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 603

REST OF EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 604

REST OF EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 605

REST OF EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 606

REST OF EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 607

REST OF EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 608

REST OF EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 609

REST OF EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 610

REST OF EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 611

REST OF EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 612

REST OF EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 613

ASIA PACIFIC: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 614

ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 615

ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 616

ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 617

ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 618

ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 619

ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 620

ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 621

ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 622

ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 623

ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 624

ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 625

ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 626

ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 627

ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 628

ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 629

ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 630

CHINA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 631

CHINA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 632

CHINA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 633

CHINA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 634

CHINA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 635

CHINA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 636

CHINA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 637

CHINA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 638

CHINA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 639

CHINA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 640

CHINA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 641

CHINA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 642

CHINA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 643

CHINA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 644

CHINA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 645

CHINA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 646

JAPAN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 647

JAPAN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 648

JAPAN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 649

JAPAN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 650

JAPAN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 651

JAPAN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 652

JAPAN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 653

JAPAN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 654

JAPAN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 655

JAPAN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 656

JAPAN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 657

JAPAN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 658

JAPAN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 659

JAPAN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 660

JAPAN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 661

JAPAN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 662

SOUTH KOREA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 663

SOUTH KOREA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 664

SOUTH KOREA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 665

SOUTH KOREA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 666

SOUTH KOREA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 667

SOUTH KOREA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 668

SOUTH KOREA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 669

SOUTH KOREA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 670

SOUTH KOREA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 671

SOUTH KOREA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 672

SOUTH KOREA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 673

SOUTH KOREA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 674

SOUTH KOREA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 675

SOUTH KOREA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 676

SOUTH KOREA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 677

SOUTH KOREA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 678

INDIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 679

INDIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 680

INDIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 681

INDIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 682

INDIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 683

INDIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 684

INDIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 685

INDIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 686

INDIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 687

INDIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 688

INDIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 689

INDIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 690

INDIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 691

INDIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 692

INDIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 693

INDIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 694

AUSTRALIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 695

AUSTRALIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 696

AUSTRALIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 697

AUSTRALIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 698

AUSTRALIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 699

AUSTRALIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 700

AUSTRALIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 701

AUSTRALIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 702

AUSTRALIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 703

AUSTRALIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 704

AUSTRALIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 705

AUSTRALIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 706

AUSTRALIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 707

AUSTRALIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 708

AUSTRALIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 709

AUSTRALIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 710

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 711

REST OF ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 712

REST OF ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 713

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 714

REST OF ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 715

REST OF ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 716

REST OF ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 717

REST OF ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 718

REST OF ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 719

REST OF ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 720

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 721

REST OF ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 722

REST OF ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 723

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 724

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 725

REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 726

LATIN AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 727

LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 728

LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 729

LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 730

LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 731

LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 732

LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 733

LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 734

LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 735

LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 736

LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 737

LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 738

LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 739

LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 740

LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 741

LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 742

LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 743

BRAZIL: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 744

BRAZIL: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 745

BRAZIL: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 746

BRAZIL: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 747

BRAZIL: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 748

BRAZIL: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 749

BRAZIL: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 750

BRAZIL: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 751

BRAZIL: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 752

BRAZIL: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 753

BRAZIL: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 754

BRAZIL: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 755

BRAZIL: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 756

BRAZIL: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 757

BRAZIL: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 758

BRAZIL: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 759

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 760

REST OF LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 761

REST OF LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 762

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 763

REST OF LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 764

REST OF LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 765

REST OF LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 766

REST OF LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 767

REST OF LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 768

REST OF LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 769

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 770

REST OF LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 771

REST OF LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 772

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 773

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 774

REST OF LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 775

MIDDLE EAST: MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 776

MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 777

MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 778

MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 779

MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 780

MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 781

MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 782

MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 783

MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 784

MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 785

MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 786

MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 787

MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 788

MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 789

MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 790

MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 791

MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 792

GCC COUNTRIES: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 793

GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 794

GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 795

GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 796

GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 797

GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 798

GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 799

GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 800

GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 801

GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 802

GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 803

GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 804

GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 805

GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 806

GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 807

GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 808

GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 809

SAUDI ARABIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 810

SAUDI ARABIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 811

SAUDI ARABIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 812

SAUDI ARABIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 813

SAUDI ARABIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 814

SAUDI ARABIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 815

SAUDI ARABIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 816

SAUDI ARABIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 817

SAUDI ARABIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 818

SAUDI ARABIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 819

SAUDI ARABIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 820

SAUDI ARABIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 821

SAUDI ARABIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 822

SAUDI ARABIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 823

SAUDI ARABIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 824

SAUDI ARABIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 825

UAE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 826

UAE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 827

UAE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 828

UAE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 829

UAE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 830

UAE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 831

UAE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 832

UAE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 833

UAE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 834

UAE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 835

UAE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 836

UAE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 837

UAE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 838

UAE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 839

UAE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 840

UAE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 841

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 842

REST OF GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 843

REST OF GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 844

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 845

REST OF GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 846

REST OF GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 847

REST OF GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 848

REST OF GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 849

REST OF GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 850

REST OF GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 851

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 852

REST OF GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 853

REST OF GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 854

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 855

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 856

REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 857

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 858

REST OF MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 859

REST OF MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 860

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 861

REST OF MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 862

REST OF MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 863

REST OF MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 864

REST OF MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 865

REST OF MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 866

REST OF MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 867

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 868

REST OF MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 869

REST OF MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 870

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 871

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 872

REST OF MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 873

AFRICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)

TABLE 874

AFRICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 875

AFRICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 876

AFRICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 877

AFRICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 878

AFRICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 879

AFRICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 880

AFRICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 881

AFRICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 882

AFRICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)

TABLE 883

AFRICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)

TABLE 884

AFRICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 885

AFRICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)

TABLE 886

AFRICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)

TABLE 887

AFRICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)

TABLE 888

AFRICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 889

OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS

TABLE 890

MULTIOMICS MARKET: DEGREE OF COMPETITION

TABLE 891

MULTIOMICS MARKET: REGION FOOTPRINT

TABLE 892

MULTIOMICS MARKET: OFFERING FOOTPRINT

TABLE 893

MULTIOMICS MARKET: TECHNOLOGY FOOTPRINT

TABLE 894

MULTIOMICS MARKET: WORKFLOW FOOTPRINT

TABLE 895

MULTIOMICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS

TABLE 896

MULTIOMICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 897

MULTIOMICS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 898

MULTIOMICS MARKET: DEALS, JANUARY 2023–JULY 2026

TABLE 899

MULTIOMICS MARKET: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 900

10X GENOMICS: COMPANY OVERVIEW

TABLE 901

10X GENOMICS: PRODUCTS & SERVICES OFFERED

TABLE 902

10X GENOMICS, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 903

10X GENOMICS, INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 904

THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 905

THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED

TABLE 906

THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 907

THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 908

ILLUMINA, INC.: COMPANY OVERVIEW

TABLE 909

ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED

TABLE 910

ILLUMINA, INC: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 911

ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 912

OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW

TABLE 913

OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS & SERVICES OFFERED

TABLE 914

OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023–JULY 2026

TABLE 915

OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 916

BRUKER: COMPANY OVERVIEW

TABLE 917

BRUKER: PRODUCTS & SERVICES OFFERED

TABLE 918

BRUKER : PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 919

BRUKER : DEALS, JANUARY 2023–JULY 2026

TABLE 920

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY OVERVIEW

TABLE 921

PACBIO.: PRODUCTS & SERVICES OFFERED

TABLE 922

PACBIO.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 923

PACBIO.: DEALS, JANUARY 2023–JULY 2026

TABLE 924

DANAHER CORPORATION: COMPANY OVERVIEW

TABLE 925

DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED

TABLE 926

DANAHER CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 927

DANAHER CORPORATION: DEALS, JANUARY 2023–JULY 2026

TABLE 928

VIZGEN, INC.: COMPANY OVERVIEW

TABLE 929

VIZGEN, INC.: PRODUCTS & SERVICES OFFERED

TABLE 930

VIZGEN, INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 931

AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW

TABLE 932

AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED

TABLE 933

AGILENT TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 934

AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 935

AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 936

BIOGNOSYS: COMPANY OVERVIEW

TABLE 937

BIOGNOSYS: PRODUCTS & SERVICES OFFERED

TABLE 938

BIOGNOSYS: DEALS, JANUARY 2023–JULY 2026

TABLE 939

MERCK KGAA: COMPANY OVERVIEW

TABLE 940

MERCK KGAA: PRODUCTS & SERVICES OFFERED

TABLE 941

MERCK KGAA: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 942

QIAGEN: COMPANY OVERVIEW

TABLE 943

QIAGEN: PRODUCTS & SERVICES OFFERED

TABLE 944

QIAGEN: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 945

QIAGEN: DEALS, JANUARY 2023–JULY 2026

TABLE 946

QIAGEN: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 947

REVVITY: COMPANY OVERVIEW

TABLE 948

REVVITY: PRODUCTS & SERVICES OFFERED

TABLE 949

REVVITY: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 950

REVVITY: DEALS, JANUARY 2023–JULY 2026

TABLE 951

WATERS CORPORATION: COMPANY OVERVIEW

TABLE 952

WATERS CORPORATION: PRODUCTS & SERVICES OFFERED

TABLE 953

WATERS CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 954

WATERS CORPORATION: DEALS, JANUARY 2023–JULY 2026

TABLE 955

WATERS CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 956

BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW

TABLE 957

BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED

TABLE 958

BIO-RAD LABORATORIES, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 959

BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–JULY 2026

TABLE 960

TAKARA BIO INC.: COMPANY OVERVIEW

TABLE 961

TAKARA BIO INC.: PRODUCTS & SERVICES OFFERED

TABLE 962

TAKARA BIO INC.: EXPANSIONS, JANUARY 2023–JULY 2026

TABLE 963

METABOLON, INC.: COMPANY OVERVIEW

TABLE 964

METABOLON, INC.: PRODUCTS & SERVICES OFFERED

TABLE 965

METABOLON, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026

TABLE 966

BGI GENOMICS CO., LTD.: COMPANY OVERVIEW

TABLE 967

NOVOGENE CO., LTD.: COMPANY OVERVIEW

TABLE 968

AZENTA, INC.: COMPANY OVERVIEW

TABLE 969

EVOTEC SE: COMPANY OVERVIEW

TABLE 970

MEDGENOME LABS LTD.: COMPANY OVERVIEW

TABLE 971

CD GENOMICS: COMPANY OVERVIEW

TABLE 972

BIOGENITY: COMPANY OVERVIEW

TABLE 973

SAPIENT BIOANALYTICS, LLC: COMPANY OVERVIEW

TABLE 974

RAYBIOTECH, INC.: COMPANY OVERVIEW

TABLE 975

SOURCE BIOSCIENCE LTD.: COMPANY OVERVIEW

TABLE 976

IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

FIGURE 1

MARKETS COVERED AND REGIONS CONSIDERED

FIGURE 3

GLOBAL MULTIOMICS MARKET, 2024–2031

FIGURE 4

MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIOMICS MARKET, 2023–2026

FIGURE 5

DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET

FIGURE 6

HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031

FIGURE 7

ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD

FIGURE 8

RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET

FIGURE 9

PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025

FIGURE 10

INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 11

PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 12

MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 13

MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS

FIGURE 14

MULTIOMICS MARKET: VALUE CHAIN ANALYSIS

FIGURE 15

MULTIOMICS MARKET: ECOSYSTEM ANALYSIS

FIGURE 16

AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)

FIGURE 17

AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD)

FIGURE 18

AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD)

FIGURE 19

AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD)

FIGURE 20

MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

FIGURE 21

INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET

FIGURE 22

TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025

FIGURE 23

IMPACT OF AI/GEN AI ON MULTIOMICS MARKET

FIGURE 24

NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT

FIGURE 25

ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT

FIGURE 26

REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)

FIGURE 27

MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025

FIGURE 28

MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025

FIGURE 29

MULTIOMICS MARKET: COMPANY FOOTPRINT

FIGURE 30

MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025

FIGURE 31

YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 32

EV/EBITDA OF KEY VENDORS

FIGURE 33

MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON

FIGURE 34

10X GENOMICS: COMPANY SNAPSHOT (2025)

FIGURE 35

THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)

FIGURE 36

ILLUMINA, INC.: COMPANY SNAPSHOT (2025)

FIGURE 37

OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)

FIGURE 38

BRUKER: COMPANY SNAPSHOT (2025)

FIGURE 39

PACBIO.: COMPANY SNAPSHOT (2025)

FIGURE 40

DANAHER CORPORATION: COMPANY SNAPSHOT (2025)

FIGURE 41

AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)

FIGURE 42

MERCK KGAA: COMPANY SNAPSHOT (2025)

FIGURE 43

QIAGEN: COMPANY SNAPSHOT (2025)

FIGURE 44

REVVITY: COMPANY SNAPSHOT (2025)

FIGURE 45

WATERS CORPORATION: COMPANY SNAPSHOT (2025)

FIGURE 46

BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)

FIGURE 47

TAKARA BIO INC.: COMPANY SNAPSHOT (2025)

FIGURE 48

RESEARCH DESIGN

FIGURE 49

MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES

FIGURE 50

MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025

FIGURE 51

MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025

FIGURE 52

REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC. (2025)

FIGURE 53

MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 54

MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 55

MULTIOMICS MARKET CAGR PROJECTIONS

FIGURE 56

DATA TRIANGULATION METHODOLOGY

Methodology

This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Multiomics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Multiomics Market : Top-Down and Bottom-Up Approach

Multiomics Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

Key Stakeholders

Multiomics product & service providers
Multiomics bioinformatics/data analysis companies
Venture capitalists and other government funding organizations
Research and consulting firms
Hospitals and diagnostic clinics
Pharmaceutical and biotechnology companies
Academic and government research institutes
Life science companies

Report Objectives

To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
To profile the key players and analyze their market shares and core competencies
To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

Further breakdown of the Rest of Europe multiomics market, by country
Further breakdown of the Rest of Asia Pacific multiomics market, by country

Company Analysis

Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

Personalize This Research

Triangulate with your Own Data
Get Data as per your Format and Definition
Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
Any level of Personalization

Request A Free Customisation

Let Us Help You

What are the Known and Unknown Adjacencies Impacting the Multiomics Market
What will your New Revenue Sources be?
Who will be your Top Customer; what will make them switch?
Defend your Market Share or Win Competitors
Get a Scorecard for Target Partners

Customized Workshop Request

JAYANT RAJPUROHIT

Director of Market Insights, Data and Analytics

SFI Health,

Leading Pharmaceutical Company

www.sfihealth.com/

We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.

BEATRIZ DE LA CALLE

Head of Commercial Analytics

Qualicaps,

Leading Pharmaceutical Company

www.qualicaps.com/

We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.

Bob Williams,

Senior Director Business Development & Innovation

Bracco Diagnostics Inc.,

Italian Multinational in life sciences sector and a World Leader in imaging diagnostics

imaging.bracco.com/us-en

We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.

Cody Coonradt,

Market Development and Strategy Manager

3M Health Information Systems,

Leader in Health care Coding, Payment & Analytics Solutions.

www.3m.com/3M/en_US/health-information-systems-us

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.

Their customer first approach and high value engagement model, have given us great analysis and excellent value for money

Previous Next

Схожие новости

#	Наименование новости	Информативность	Дата публикации
1	Blood Culture Tests Market by Product (Consumables, Instruments), Method (Manual, Automated), Technology (Culture-Based, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospital, Academic Research), Region - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	14.52	12-08-2026
2	Anatomic Pathology Market by Product [Consumables (Histopathology, Cytopathology), Instruments, Software], Process, Disease (Breast, GI, Prostate), End User (Hospitals, Research Labs), Services, Model (In House, Outsourced) Global Forecast to 2031..., Market Research Report: MarketsandMarkets	11.67	07-08-2026
3	Care Management Solutions Market by Component [Software (Integrated, Standalone)], Application (Chronic Care, Preventive, Utilization, Transitional), Deployment (On-prem, Cloud), End User (Hospital, ASC, Public & Private Payer) - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	14.39	07-08-2026
4	Animal Genetics Market by Live Animal (Bovine, Porcine, Canine), Products & Services (Genetic Materials (Semen, Embryo), Genetic Testing Services (Disease Tests, Trait Tests), Technology (PCR, NGS, rDNA), End User (Animal Farm) - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	9.33	31-07-2026
5	Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, HIFU), Product (Systems, Consumables), Application (Liver, Lung, Kidney, Bone Cancer), Procedure (Surgical, Laparoscopic, Percutaneous), and End User - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	12.28	03-08-2026
6	Weather Monitoring Systems Market by Solution (Weather Stations, Weather Radars, Wind LiDARs), Application (Meteorology, Aviation, Agriculture, Defense, Marine, Energy), Form Factor, Connectivity, Performance Grade, and Region - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	10.97	04-08-2026
7	Research Use (RUO) Recombinant Protein Market by Product (Cytokines, Growth Factors), Formulation (Lyophilized, Liquid), Species (Human, Mouse), Host (Mammalian, Yeast), Application (Cell Culture), End User, Competition, Region - Global Forecast to 2031..., Market Research Report: MarketsandMarkets	11.54	04-08-2026
8	Fixed Fire & Gas Detection Systems Market by Product (Fire Detection Systems, Fixed Gas Detection Systems, Fire & Gas Control Systems, Fire Alarm & Notification Systems), Detection Technology, Hazard Type, End User, and Region Global Forecast to 2031..., Market Research Report: MarketsandMarkets	5.75	03-08-2026
9	Veterinary Monitoring Equipment Market by Type (Anesthesia Machine, Capnography System, ECG & Holter Monitoring, Telemetry, Vital Signs Monitor), Technology (Wireless Patient Monitor, Wired Monitoring System), End User Global Forecast to 2031..., Market Research Report: MarketsandMarkets	9.78	11-08-2026
10	Laboratory Freezers Market by Modality (Cryopreservation; Freezer: ULTF, Plasma, Enzyme; Refrigerator: Blood Bank, Pharmacy, Chromatography), Application (Genetic, Vaccine, Biological Sample), End User (Hospital, Pharma, Cell Bank)-Global Forecast to 2031..., Market Research Report: MarketsandMarkets	15.28	30-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.28. Источник: www.marketsandmarkets.com.

Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031 ..., Market Research Report: MarketsandMarkets

Дата публикации: 06-08-2026 00:00:00

Основное содержимое страницы с новостью.

Схожие новости